# Nuclide record opp-nectin4-imaging-urothelial (opportunity). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/opportunities/opp-nectin4-imaging-urothelial/>
  a schema:CreativeWork ;
  nuclide:kind "opportunity" ;
  schema:identifier "opp-nectin4-imaging-urothelial" ;
  schema:name "A liver-cleared Nectin-4 tracer for urothelial cancer"@en ;
  schema:alternateName "Nectin-4 PET"@en, "nectin-4 imaging"@en ;
  schema:description "An approved bladder cancer drug works by latching onto a protein called Nectin-4, and half of patients lose that protein as the disease spreads. The one scan built to show it is cleared through the kidneys, so the bladder and the nearby lymph nodes glow with waste tracer and are the hardest places to read."@en ;
  schema:url <https://nuclide.cc/opportunities/opp-nectin4-imaging-urothelial/> ;
  schema:dateModified "2026-09-23"^^xsd:date ;
  schema:citation <https://pubmed.ncbi.nlm.nih.gov/37093191/>, <https://pubmed.ncbi.nlm.nih.gov/38719240/>, <https://pmc.ncbi.nlm.nih.gov/articles/PMC12227459/>, <https://aacrjournals.org/clincancerres/article/29/8/1496/725070/Membranous-NECTIN-4-Expression-Frequently>, <https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-enfortumab-vedotin-ejfv-muscle-invasive-bladder-cancer> ;
  nuclide:tag "theranostic gap", "bladder", "clearance", "pelvic staging" ;
  nuclide:related <https://nuclide.cc/isotopes/ga-68/>, <https://nuclide.cc/isotopes/f-18/> ;
  nuclide:indications <https://nuclide.cc/indications/urothelial-cancer/> ;
  nuclide:technologies <https://nuclide.cc/technologies/pet-ct/>, <https://nuclide.cc/technologies/peptide-drug-conjugate/> ;
  nuclide:targets <https://nuclide.cc/targets/nectin4/> .